Literature DB >> 10891651

Enhanced resistance to experimental systemic candidiasis in tilorone-treated mice.

E Ortega1, I Algarra, M J Serrano, M A de Pablo, G Alvarez de Cienfuegos, J J Gaforio.   

Abstract

Candida albicans is an increasingly important opportunistic fungal pathogen in immunocompromised patients. Natural killer (NK) cells constitute an important immune effector mechanism and are involved in the response to different pathological disorders. We wished to determine if this immune mechanism is involved in the specific response to C. albicans. Tilorone hydrochloride and related compounds have been described to display antiviral and antitumoral activity, as well as to enhance NK cell activity. In this study, we show the antimicrobial activity of different tilorone analogues and the enhanced resistance of tilorone-treated mice in experimental systemic candidiasis. We also present data suggesting that there is a correlation between NK cell activation and the resistance to experimental systemic candidiasis. Thus, it seems that the immunosurveillance of metastatic spread and the infection by C. albicans share some immune effector mechanisms, in particular activation of NK cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10891651     DOI: 10.1111/j.1574-695X.2000.tb01488.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  2 in total

1.  NK cells mediate increase of phagocytic activity but not of proinflammatory cytokine (interleukin-6 [IL-6], tumor necrosis factor alpha, and IL-12) production elicited in splenic macrophages by tilorone treatment of mice during acute systemic candidiasis.

Authors:  José Juan Gaforio; Elena Ortega; Ignacio Algarra; María José Serrano; Gerardo Alvarez de Cienfuegos
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

2.  Successful treatment of antifungal- and cryotherapy-resistant subcutaneous hyalohyphomycosis in an immunocompetent case with topical 5% imiquimod cream.

Authors:  Zulal Erbagci; A Almila Tuncel; Suna Erkilic; Yasemin Zer
Journal:  Mycopathologia       Date:  2005-06       Impact factor: 2.574

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.